The Emirates Drug Establishment has conditionally approved a new indication for AstraZeneca’s Ultomiris to reduce proteinuria in adults with primary immunoglobulin A nephropathy who face a high risk of disease progression. The regulatory body announced the decision on November 10, 2026, underscoring the UAE’s commitment to accelerating patient access to innovative therapies while maintaining rigorous standards for safety and efficacy. This marks the first worldwide approval for the complement inhibitor in this specific use, building on the medicine’s existing registration in the country since 2022 for several rare diseases.
Primary immunoglobulin A nephropathy is an immune-mediated condition in which abnormal deposits of immunoglobulin A trigger inflammation in the kidneys, often leading to a progressive decline in organ function over time. A review published in Seminars in Nephrology highlighted considerable geographic variation in incidence, with rates rising from west to east across Eurasia due in part to genetic factors and differences in screening and biopsy practices. Data cited in a JAMA Network article placed the annual incidence between 0.76 and 2.2 per 100,000 people depending on the region, with prevalence estimates reaching 54 to 63 per 100,000 in the United States alone.
Interim results from the phase 3 I CAN trial, published in the New England Journal of Medicine, showed that ravulizumab produced a 46.6 percent reduction in the 24-hour urine protein-to-creatinine ratio at week 34, compared with a 5.6 percent reduction in the placebo arm. The adjusted between-group difference reached 43.4 percent, meeting the primary endpoint with statistical significance, and the safety profile remained consistent with previous uses of the therapy. According to the Emirates Drug Establishment, the conditional approval followed a comprehensive scientific assessment that balanced the need for timely innovation against requirements for quality and evidence of benefit.
Ruqaya Aqeel Al Bastaki, Acting Executive Director of the Medical Products Regulation Sector at the Emirates Drug Establishment, said the approval reflects the Establishment’s commitment to strengthening the pharmaceutical sector’s readiness to respond to scientific developments and emerging treatments, reinforcing the UAE’s position among the leading countries in pharmaceutical regulation. She added that the decision aligns with the strategic priorities of the We the UAE 2031 vision, which seeks to enhance competitiveness in healthcare and advance research and development. The framework adopted by the authority enables rapid yet evidence-based responses to new therapies for complex conditions.
The medicine, administered as an intravenous infusion every eight weeks, joins a growing portfolio of options available to nephrologists managing glomerular diseases in the UAE. Records from the Emirates Drug Establishment indicate that Ultomiris was first registered locally in 2022 for indications including paroxysmal nocturnal haemoglobinuria and atypical haemolytic uremic syndrome. Expansion to immunoglobulin A nephropathy broadens its reach to a condition that accounts for a substantial share of primary glomerular diagnoses globally.
Sameh El Fangary, Gulf Cluster President at AstraZeneca, described the conditional approval as an important step towards expanding the treatment options available to eligible patients in the UAE. He stated that the company looks forward to continuing its collaboration with partners in the country to support access to this treatment, helping improve outcomes and enhance the quality of care. The pharmaceutical group is conducting further follow-up in the I CAN study to verify longer-term clinical benefits.
Epidemiological assessments published in Health.com place worldwide prevalence at roughly 60 cases per 100,000 people, with new cases occurring at rates of two to three per 100,000 annually in many populations. Higher reported incidence in East Asia, sometimes exceeding four new cases per 100,000, partly reflects systematic urine screening programmes that detect mild cases earlier than in other regions. The Emirates Drug Establishment’s latest action adds to a series of regulatory steps that have positioned the UAE among early adopters of advanced therapies for kidney disorders.
ع